Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Share-based Compensation (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Share-based Compensation for 14 consecutive years, with $3.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 32.76% year-over-year to $3.8 million, compared with a TTM value of $16.7 million through Dec 2025, down 31.41%, and an annual FY2025 reading of $18.6 million, down 30.71% over the prior year.
  • Share-based Compensation was $3.8 million for Q4 2025 at Enanta Pharmaceuticals, down from $4.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $8.1 million in Q4 2023 and bottomed at $3.8 million in Q4 2025.
  • Average Share-based Compensation over 5 years is $6.0 million, with a median of $5.9 million recorded in 2021.
  • The sharpest move saw Share-based Compensation surged 38.87% in 2022, then crashed 47.73% in 2025.
  • Year by year, Share-based Compensation stood at $6.1 million in 2021, then increased by 17.77% to $7.1 million in 2022, then increased by 13.45% to $8.1 million in 2023, then plummeted by 30.04% to $5.7 million in 2024, then crashed by 32.76% to $3.8 million in 2025.
  • Business Quant data shows Share-based Compensation for ENTA at $3.8 million in Q4 2025, $4.0 million in Q3 2025, and $4.2 million in Q2 2025.